Atropos Well being, an organization that interprets real-world medical information (RWD) into real-world proof, introduced a strategic partnership with Ontada, a McKesson enterprise concerned in neighborhood oncology.
Ontada is related to The US Oncology Community, an entirely owned subsidiary of McKesson, which delivers real-time information, insights and analysis on how most cancers is handled in a neighborhood.
The collaboration goals to strengthen the use instances for clinicians, researchers and healthcare leaders to design care protocols, promote precision drugs and create new therapies in oncology.
Atropos Well being’s automation instruments produce proof from a buyer’s information by putting in GENEVA OS, its working system for speedy healthcare proof, into clients’ inside cloud information setting and the Atropos Proof Community.
Members of the Proof Community can leverage longitudinal affected person information from collaborating Community sources, giving them entry to deidentified affected person data whereas preserving information possession and safety.
Members also can run queries on the RWD within the Atropos Proof Community and entry information for every query the Actual-World Health Rating evaluates.
The collaboration follows Atropos Well being’s March announcement of Federated Nodal Deidentification Expertise, which can be added to the GENEVA OS platform and accessible to Atropos Proof Community members.
In line with the corporate, Nodal Deidentification permits customers to fill information gaps in sufferers’ longitudinal data from collaborating Atropos Proof Community sources.
“The demand for high-quality information in oncology is ever current,” Brigham Hyde, CEO and cofounder of Atropos Well being, stated in an announcement.
“The Atropos Proof Community, which is able to now embody Ontada’s RWD, contains advantages throughout your complete healthcare ecosystem. For well being techniques, the oncology multi-modal community comprises the high-quality RWD essential to generate the RWE wanted for high-stakes medical choices.”
THE LARGER TREND
In February, Emory Healthcare partnered with Atropos Well being to advance remedy formulary choices and protocols. Emory piloted a program to advance affected person care by permitting medical inquiries to be answered in real-time utilizing Atropos’ platform.
The Atropos Proof Community permits Emory customers to run research on nationwide datasets and native Emory information. Clinicians additionally use Atropos’ Inexperienced Button to entry RWE.
In January, Atropos Well being partnered with xCures, an AI-powered healthcare information retrieval firm, to harness RWE-based insights to assist affected person care.
The partnership aimed to leverage AI, the Atropos Proof Community and the xCures Platform to develop and deploy authorised prognostic and choice assist instruments to healthcare suppliers within the healthcare ecosystem.
That very same month, Atropos partnered with Merck to generate RWE, replicate research, and produce speedy insights and analytics on real-world information.
Merck’s information science and RWE groups will make use of Atropos Well being companies, together with GENEVA OS Inexperienced Button, Atropos Proof Community and Alexandria, Forge and ChatRWD.
In 2024, Atropos secured $33 million in Collection B funding.
Valtruis led the funding spherical, which included new buyers McKesson Ventures, Merck GHI Fund and Cencora Ventures.
Present buyers Emerson Collective, Breyer Capital and Presidio Ventures additionally participated within the spherical
Mike Spadafore, managing director of Valtruis, joined the corporate’s board of administrators.
Atropos additionally introduced that the healthcare information analytics firm Arcadia joined its well being portfolio that 12 months, giving Arcadia’s supplier clients and life sciences customers entry to Atropos’ choices.
Through the partnership, Arcadia joined Atropos’ Proof Community, which gave its customers entry to Atropos’ portfolio of functions to assist medical decision-making in value-based care.
